SCHEMBL26316729

SCHEMBL26316729

Cc1ccc(-c2ccc(CO)cn2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.54
ABL1 P00519 1/20 0.54
NTRK1 P04629 1/20 0.54
LCK P06239 1/20 0.54
CSF1R P07333 1/20 0.54
RET P07949 1/20 0.54
MET P08581 1/20 0.54
PDGFRB P09619 1/20 0.54
PIM1 P11309 1/20 0.54
PDGFRA P16234 1/20 0.54
FLT3 P36888 1/20 0.54
MAPK8 P45983 1/20 0.54
CDK8 P49336 1/20 0.54
MAP2K1 Q02750 1/20 0.54
MAP4K2 Q12851 1/20 0.54
ROCK1 Q13464 1/20 0.54
NTRK3 Q16288 1/20 0.54
MAPK14 Q16539 1/20 0.54
AURKB Q96GD4 1/20 0.54
KDM1A O60341 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12970398 0.89 CCR1 (0.54) AURKAABL1NTRK1LCKCSF1R
SCHEMBL9641353 0.85 CCR1 (0.64) AURKAABL1NTRK1LCKCSF1R
SCHEMBL12684741 0.83 RAB9A (0.63) AURKAABL1NTRK1LCKCSF1R
SCHEMBL1437161 0.82 SMN1; SMN2 (0.46) KDM1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL12002675 0.81 NPC1 (0.61) ABL1KDM1ARAB9ASMN1; SMN2NPC1
SCHEMBL17954213 0.81 SMN1; SMN2 (0.66) KDM1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL2216313 0.81 FYN (0.56) AURKAABL1NTRK1LCKCSF1R
SCHEMBL6673316 0.81 AURKA (0.54) AURKAABL1NTRK1LCKCSF1R
SCHEMBL1549909 0.81 GRM2 (0.49) KDM1ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL26316731 0.81 AURKA (0.54) AURKAABL1NTRK1LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 AURKA 1524/4885ABL1 227/4885NTRK1 811/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 AURKA 1594/4885ABL1 188/4885NTRK1 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.